Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Pikralida logo — Pikralida - A drug development company

Pikralida

Pikralida - A drug development company

Founded 2019 Poland Poland 20 employees Total: $16.70M

General Information

Company Name Pikralida
Founded Year 2019
Location Poland Poland
Employees 20
Business Model B2B, B2C, B2B2C
Revenue Model Service Fee, Licensing, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Pikralida. To contact Pikralida, visit pikralida.eu.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Pikralida compare?

A PDF of Pikralida and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Pikralida soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Pikralida

Pikralida, founded in 2019 and headquartered in Poland, is a dynamic biotechnology company that seamlessly integrates the development of innovative therapies with Contract Research Organization (CRO) services. Its hybrid business model offers both proprietary drug development and partnered research opportunities, positioning the company for strategic growth in the global marketplace.

The company's flagship program revolves around PKL-021 (marimastat), a potent matrix metalloprotease (MMP) inhibitor, currently advancing in clinical trials for key indications such as neuroprotection from strokes and treatments for snakebite envenoming. These initiatives underscore its commitment to addressing high-impact therapeutic areas.

Pikralida's recent PLN13.30M Early VC investment, funded by notable investors including Tanis Ventures, Altamira, Hard2beat, and iif.vc, reflects strong backing for its global ambitions. The company's integration of CRO services enhances its value proposition by offering tailored R&D solutions to the biotech and pharmaceutical industries.

Business keywords: Contract Research Organization, Drug Development, Neuroprotection, Stroke Therapy, Snakebite Treatment, MMP Inhibitors, Pharmaceutical Research, Therapeutic Innovation, Preclinical Programs, Clinical-stage Development, Pharmaceutical Analysis, Formulation Development, Strategic Partnerships, Global Market Introduction

Services & Products

Contract Research Services
Research and Development Projects
Therapeutic Innovations

Target Customers

Pharmaceutical Companies Biotech Firms Healthcare Innovators

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC PLN13.30M 4
Tanis Ventures
Tanis Ventures, Altamira +2
01 Nov 2025
Seed PLN3.40M 1
Altamira
01 Apr 2023

Pikralida Alternatives & Competitors

View All Alternatives
Pikralida vs
Vectura Group
Vectura Group United Kingdom

We are a specialist inhalation CDMO helping you bring innovative inhaled medicines to market.

238 employees
Compare Pikralida vs Vectura Group
Pikralida vs
OrganoTherapeutics
OrganoTherapeutics Luxembourg

Using Midbrain Organoids for the development of new Therapeutics against Parkinson`s Disease.

9 employees
Biopharma, Biotechnology
Pikralida vs
ARTCLINE GmbH
ARTCLINE GmbH Germany

Innovative therapeutic procedures for Intensive Care Medicine for the treatment of severe infections...

17 employees
Biotechnology, Health Care
View all alternatives

FAQ About Pikralida

Pikralida - A drug development company
Pikralida was founded in 2019.
Pikralida is headquartered in Poland.
Pikralida has a B2B, B2C and B2B2C business model. Its revenue comes from Service Fee, Licensing and Project Based.
Pikralida has approximately 20 employees.
Pikralida has completed 2 funding rounds, raising a total of $16.70M.
Pikralida offers: Contract Research Services, Research and Development Projects, Therapeutic Innovations.
Top alternatives and competitors to Pikralida include Vectura Group, OrganoTherapeutics, ARTCLINE GmbH, Adcytherix, The Solubility Company. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pikralida and Vectura Group are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Pikralida, https://bouncewatch.com/company/pikralida, updated 2 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout